Emerging drugs for the treatment of sepsis

Expert Opinion on Emerging Drugs

Volumn 17, Issue 3, 2012, Pages 379-391

  Kotsaki, Antigone ^a   Giamarellos Bourboulis, Evangelos J ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Cytokines; Hydrocortisone; Immunoglobulins; Macrolides; Polymyxin B; Sepsis

Indexed keywords

AFELIMOMAB; ANTICOAGULANT AGENT; BACTERIUM LIPOPOLYSACCHARIDE; CD14 ANTIGEN; CLARITHROMYCIN; CYTOFAB; CYTOKINE; DROTRECOGIN; GAMMA INTERFERON; GLUCOCORTICOID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; HYDROCORTISONE; IMMUNOGLOBULIN G; INSULIN; INTERLEUKIN 6; INTERLEUKIN 8; MACROLIDE; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; POLYMYXIN B; POLYUNSATURATED FATTY ACID; RECOMBINANT GAMMA INTERFERON; RECOMBINANT THROMBOMODULIN; RESATORVID; TALACTOFERRIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; HEMOPERFUSION; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; MORTALITY; NUTRITION; PROTEIN EXPRESSION; REVIEW; SEPSIS; SEPTIC SHOCK; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; ANTICOAGULANTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; GLUCOCORTICOIDS; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; SEPSIS; TREATMENT OUTCOME;

EID: 84865600308     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2012.697151     Document Type: Review

References (92)

1. Giamarellos-Bourboulis EJ, Raftogiannis M. The immune response to severe bacterial infections: consequences for therapy. Exp Rev Anti Infect Ther 2012;10:369-80
2. Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 2010;10:479-90
3. Giamarellos-Bourboulis EJ, van de Veerdonk FL, Mouktaroudi M, et al. Inhibition of caspase-1 activation in Gram-negative sepsis and experimental endotoxemia. Crit Care 2011;15:R27
4. Weber M, Lambeck S, Ding N, et al. Hepatic induction of cholesterol biosynthesis reflects a remote adaptive response to pneumococcal pneumonia. FASEB J 2012; [Epub ahead of print]
5. Reddy RC, Standiford TJ. Effects of sepsis on neutrophil chemotaxis. Curr Opin Hematol 2010;17:18-24
6. Mann EA, Baun MM, Meininger JC, et al. Comparison of mortality associated with sepsis in the burn, trauma and general intensive care unit patient: a systemic review of the literature. Shock 2012;37:4-16
7. Rodriguez F, Barrera L, De La Rosa G, et al. The epidemiology of sepsis in Colombia: a prospective multicenter cohort study in ten university hospitals. Crit Care Med 2011;39:1675-82
8. Shen HN, Lu CL, Yang HH. Epidemiologic trend of severe sepsis in Taiwan from 1997 through 2006. Chest 2010;138:116-23
9. Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327
10. Ferrer R, Artigas A, Suarez D, et al. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med 2009;180:861-6
11. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-96 (Pubitemid 43810035)
12. Kumar A, Zarychanski R, Light B, et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 2010;38:1773-8
13. Hellenic Sepsis Study Group. Available from: http://www.sepsis.gr
14. Canton E, Peman J, Quindos G, et al. Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis isolated from patients with candidemia. Antimicrob Agents Chemother 2011;55:5590-6
15. Lortholary O, Desnos-Ollivier M, Sitbon K, et al. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother 2011;55:532-8
16. Kumar G, Kumar A, Tanela A, et al. Nationwide trends of severe sepsis in the 21st century (2000-2007). Chest 2011;140:1223-31
17. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;9:1303-10 (Pubitemid 32641789)
18. Vincent JL, Sun Q, Dubois MJ. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 2003;34:1084-93
19. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709 (Pubitemid 32204987)
20. Available from: http://www.xigris.com
21. Salomao R,Martins PS, Brunialti MK, et al. TLR signaling pathway in patients with sepsis. Shock 2008;30(Suppl 1):73-7
22. Sha T, Sunamoto M, Kitazaki T, et al. Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model. Eur J Pharmacol 2007;571:231-9 (Pubitemid 47379694)
23. Sha T, Iizawa Y, Ii M. Combination of imipenem and TAK-242, a toll-like receptor 4 signal transduction inhibitor, improves survival in a murine model of polymicrobial sepsis. Shock 2011;35:205-9
24. Rice TW, Wheeler AP, Bernard GR, et al. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med 2010;38:1685-94
25. Efficacy and safety of resatorvid in patients with sepsis-induced cardiovascular and respiratory failure. Available from: http://clinicaltrials. gov/ct2/show/NCT00633477
26. Cruz DN, Perazella MA, Bellomo R, et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care 2007;11:R47
27. Vincent JL, Laterre PF, Cohen J, et al. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 2005;23:400-5 (Pubitemid 40571661)
28. Mitaka C, Tsuchida N, Kawada K, et al. A longer duration of polymyxin B-immobilized fiber column hemoperfusion improves pulmonary oxygenation in patients with septic shock. Shock 2009;32:478-83
29. Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009;301:2445-52
30. Berto P, Ronco C, Cruz D, et al. Cost-effectiveness analysis of polymyxin-B immobilized fiber column and conventional medical therapy in the management of abdominal septic shock in Italy. Blood Purif 2011;32:331-40
31. Naka T, Shinozaki M, Akizawa T, et al. The effect of continuous veno-venous hemofiltration or direct hemoperfusion with polymyxinB-immobilized fiber on neutrophil respiratory oxidative burst in patients with sepsis and septic shock. Ther Apher Dial 2006;10:7-11
32. Kumagai T, Takeyama N, Yabuki T, et al. Apheresis of activated leukocytes with an immobilized polymyxin B filter in patients with septic shock. Shock 2010;34:461-6
33. Conrad U, Plagmann I, Malchow S, et al. ELPylated anti-human TNF therapeutic single-domain antibodies for prevention of lethal septic shock. Plant Biotechnol J 2011;9:22-31
34. Panacek EA, Marshall JC, Albertson TE, et al. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004;32:2173-82 (Pubitemid 39491795)
35. Rice TW, Wheeler AP, Morris PE, et al. Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha ovine fab for infection (CytoFab) in severe sepsis. Crit Care Med 2006;34:2271-81 (Pubitemid 44260009)
36. Wang X, Nelin LD, Kuhlman JR, et al. The role of MAP kinase phosphatase-1 in the protective mechanism of dexamethasone against endotoxemia. Life Sci 2008;83:671-80
37. Giamarellos-Bourboulis EJ, Dimopoulou I, Kotanidou A, et al. Ex-vivo effect of dexamethasone on cytokine production from whole blood of septic patients: correlation with disease severity. Cytokine 2010;49:89-94
38. Kaufmann I, Briegel J, Schliephake F, et al. Stress doses of hydrocortisone in septic shock: beneficial effects on opsonization-dependent neutrophil functions. Intensive Care Med 2008;34:344-9 (Pubitemid 351207639)
39. Annane D, Maxime V, Ibrahim F, et al. Diagnosis of adrenal insufficiency in severe sepsis and septic shock. Am J Respir Crit Care Med 2006;174:1319-26 (Pubitemid 44913033)
40. Annane D, Sebille V, Bellissant E, et al. Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. Crit Care Med 2006;34:22-30 (Pubitemid 43032376)
41. Keh D, Boehnke T, Weber-Cartens S, et al. Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, cross-over study. Am J Respir Crit Care Med 2003;167:512-20
42. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111-24
43. Huh JW, Choi HS, Lim CM, et al. Low-dose hydrocortisone treatment for patients with septic shock: a pilot study comparing 3 days with 7days. Respirology 2011;16:1088-95
44. Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005;171:242-8
45. Meijvis SCA, Hardeman H, Remmelts HHF, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet 2011;377:2023-30
46. Extended Steroid in CAP(e) Trial. Available from: http://clinicaltrials. gov/ct2/show/record/NCT01283009
47. Zimmerman JJ, Williams MD. Adjunctive corticosteroid therapy in pediatric severe sepsis: observations from the RESOLVE study. Pediatr Crit Care Med 2011;12:2-8
48. Savioli M, Cugno M, Polli F, et al. Tight glycemic control may favor fibrinolysis in patients with sepsis. Crit Care Med 2009;37:424-31
49. Langouche L, Meersseman W, Vander Perre S, et al. Effect of insulin therapy on coagulation and fibrinolysis in medical intensive carepatients. Crit Care Med 2008;36:1475-80 (Pubitemid 351620651)
50. van den Berghe G, Wouters P. Weekers, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359-67
51. van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006;354:449-61 (Pubitemid 43200296)
52. Finfer S, Chittock DR, Su SYS, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283-97
53. van den Berghe G, Schetz M, Vlasselaers D, et al. Intensive insulin therapy in critically ill patients: NICE-SUGAR or Leuwen blood glucose target? J Clin Endocrinol Metab 2009;94:3163-70
54. Verhoeven JJ, den Brinker M, Hokken-Koelega ACS, et al. Pathophysiological aspects of hyperglycemia in children with meningococcal sepsis and septic shock: a prospective, observational cohort study. Crit Care 2011;15:R44
55. Cai Y, Chai D, Wnag R, et al. Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review. J Antimicrob Chemother 2011;66:968-78
56. Mouktaroudi M, Giamarellos-Bourboulis EJ. Macrolides for the therapy of nosocomial infections. Curr Opin Infect Dis 2012;25:205-10
57. Martin-Loeches I, Lisboa T, Rodriguez A, et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010;36:612-20
58. Restrepo MI, Mortensen EM, Waterer GW, et al. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J 2009;33:153-9
59. Giamarellos-Bourboulis EJ, Pechere JC, Routsi C, et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis 2008;46:1157-64 (Pubitemid 351589897)
60. Spyridaki A, Raftogiannis M, Antonopoulou A, et al. The effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis by Gram-negative bacteria: results from a randomized clinical study. Antimicrob Agents Chemother 2012; Epub ahead of print
61. Available from: http://clinicaltrials.gov/ct2/show/record/NCT01223690
62. Pacht ER, DeMichele SJ, Nelson JL, et al. Enteral nutrition with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants reduces alveolar inflammatory mediators and protein influx in patients with acute respiratory distress syndrome. Crit Care Med 2003;31:491-500 (Pubitemid 36232946)
63. Singer P, Theilla M, Fisher H, et al. Benefit of an enteral diet enriched with eicosapentaenoic acid and gamma-linolenic acid in ventilated patients with acute lung injury. Crit Care Med 2006;34:1033-8
64. Pontes-Arruda A, Albuquerque Aragao AM, Albuquerque JO. Effects of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock. Crit Care Med 2006;34:2325-33 (Pubitemid 44260016)
65. Rice TW, Wheeler AP, Thompson BT, et al. Enteral omega-3 fatty acid, gamma-linolenic acid, and antioxidant supplementation in acute lung injury. JAMA 2011;306:1574-81
66. Venet F, Gebeile R, Bancel J, et al. Assessment of plasmatic immunoglobulin G, A and M levels in septic shock patients. Int Immunopharmacol 2011;11:2086-90
67. Azevedo LC, Park M, Schettino GP. Novel potential therapies for septic shock. Shock 2008;30(Suppl):60-6
68. Norrby-Teglund A, Haque KN, Hammarstr L. Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis. J Intern Med 2006;260:509-16 (Pubitemid 44772370)
69. Rodriguez A, Rello J, Neira J, et al. Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock 2005;23:298-304 (Pubitemid 40463621)
70. Neilson AR, Burchardi H, Schneider H. Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock. J Crit Care 2005;20:239-49 (Pubitemid 41505341)
71. Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med 2007;35:2686-92 (Pubitemid 350175762)
72. Kreymann KG, de Heer G, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 2007;35:2677-85 (Pubitemid 350175761)
73. Bo L, Wang F, Zhu J, et al. Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Crit Care 2011;15:R58
74. Meisel C, Schefold JC, Pschowski R, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression. Am J Respir Crit Care Med 2009;180:640-8
75. Stephens DP, Thomas JH, Higgins A, et al. Randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor in patients with septic shock. Crit Care Med 2008;36:448-54 (Pubitemid 351158618)
76. Docke WD, Randow F, Syrbe U, et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997;3:678-81 (Pubitemid 27264980)
77. Lin SM, Wang YM, Lin HC, et al. Serum thrombomodulin level relates to the clinical course of disseminated intravascular coagulation, multiorgan dysfunction syndrome, and mortality in patients with sepsis. Crit Care Med 2008;36:683-9
78. Nagato M, Okamoto K, Abe Y, et al. Recombinant human soluble thrombomodulin decreases the plasma high-mobility group box-1 protein levels, whereas improving the acute liver injury and survival rates in experimental endotoxemia. Crit Care Med 2009;37:2181-6
79. Yamakawa K, Fujimi S, Mohri T, et al. Treatment effects of recombinant soluble thrombomodulin in patients with severe sepsis: a historical control study. Crit Care 2011;15:R123
80. Available from: http://clinicaltrials.gov/ct2/show/record/NCT00487656
81. Adel M, Awad HA, Abdel-Naim AB, et al. Effects of pentoxifylline on coagulation profile and disseminated intravascular coagulation incidence in Egyptian septic neonates. J Clin Pharm Ther 2010;35:257-65
82. Dunn-Siegrist I, Leger O, Daubeuf B, et al. Pivotal involvement of Fcgamma receptor IIA in the neutralization of lipopolysaccharide signaling via a potent novel anti-TLR4 monoclonal antibody 15C1. J Biol Chem 2007;282:34817-27 (Pubitemid 350232459)
83. Gross P, Brandl K, Dierkes C, et al. Lipopolysaccharide-trap-Fc, a multifunctional agent to battle Gram-negative bacteria. Infect Immun 2009;77:2925-31
84. Rupp ME, Holley HP Jr, Lutz J, et al. Phase II, randomized, multicenter, double-blind,placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007;51:4249-54 (Pubitemid 350209873)
85. Lu Q, Rouby JJ, Laterre PF, et al. Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia. J Antimicrob Chemother 2011;66:1110-16
86. van Zoelen MA, Yang H, Florquin S, et al. Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock 2009;31:280-4
87. Bopp C, Bierhaus A, Hofer S, et al. Bench-to-bedside review: the inflammation-perpetuating patternrecognition receptor RAGE as a therapeutic target in sepsis. Crit Care 2008;12:201
88. Lutterloh EC, Opal SM, Pittman DD, et al. Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care 2007;11:22
89. Vugmeyster Y, DeFranco D, Pittman DD, et al. Pharmacokinetics and lung distribution of a humanized anti-RAGE antibody in wild-type and RAGE-/-mice. MAbs 2010;2:571-5
90. Venkatesh MP, Rong L. Human recombinant lactoferrin acts synergistically with antimicrobials commonly used in neonatal practice against coagulase-negative staphylococci and Candida albicans causing neonatal sepsis. J Med Microbiol 2008;57:1113-21
91. Available from: http://clinicaltrials.gov/ct2/show/record/NCT00630656
92. Gogos C, Kotsaki A, Pelekanou A, et al. Early alterations of the innate and adaptive immune statuses in sepsis according to the type of underlying infection. Crit Care 2010;14:R96